CSL Gains After UBS Says U.S. Sales May Beat Estimate

CSL Ltd. (CSL), the world’s second-largest maker of blood-based treatments, climbed the most in more than seven weeks in Australian trading after UBS AG (UBSN) said second-half sales in the U.S. may beat estimates.

CSL rose 2.8 percent, the most since April 14, to close at A$32.82, while Australia’s S&P/ASX 200 Index fell 0.8 percent.

U.S. sales of Melbourne-based CSL’s Privigen and Hizentra, treatments for immune-system disorders, may expand as much as 20 percent in the six months ending June 30 from a year earlier, Andrew Goodsall and Dan Hurren, analysts at UBS in Sydney, wrote in a note after the close of trading yesterday. That’s higher than the brokerage’s previous estimate of 12 percent.

Full-year profit will “meet or beat” UBS’s current estimates, said Goodsall and Hurren, who rate the stock “buy.” UBS is among 6 of 14 brokerages tracked by Bloomberg that recommend investors buy CSL shares. None has a sell rating.

To contact the reporter on this story: Simeon Bennett in Singapore at sbennett9@bloomberg.net

To contact the editor responsible for this story: Jason Gale at j.gale@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.